Return to Listing

1 result(s) for

PI Name Protocol # Title
Brandon Hayes-Lattin STUDY00019250 [NCI CIRB] A041501 - A Phase III Trial To Evaluate the Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080